Skip to main content

GlucoTrack Inc

For the period ended Mar 31, 2024. Filed May 15, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

GCTK$1.39-32.2%Stored close · as of Oct 29, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

Three-month period ended March 31,
20242023
(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES
Loss for the period$(2,927)$(1,286)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization44
Stock-based compensation2257
Issuance of restricted shares as compensation towards directors785
Linkage difference on principal of loans from stockholders(1)2
Changes in assets and liabilities:
Increase in other current assets(64)(137)
Increase (decrease) in accounts payable175(13)
Increase (Decrease) in other current liabilities(229)55
Net cash used in operating activities(2,942)(1,313)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment(59)-
Net cash used in investing activities(59)-
Effect of exchange rate changes on cash and cash equivalents, and restricted cash6(5)
Change in cash and cash equivalents, and restricted cash(2,995)(1,318)
Cash and cash equivalents, and restricted cash at beginning of the period4,5022,331
Cash and cash equivalents, and restricted cash, end of period$1,507$1,013
Three-month period ended March 31,
2024 · 2023
(Unaudited)
Supplemental disclosure of cash flow activities:
(a) Net cash paid during the year for:
Interest$28$-
(b) Non-cash activities:
Recognition of right for usage asset against a lease liability$79$-
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.